Deloitte and Sanofi have partnered up on an artificial intelligence software-as-a-service (SaaS) adverse events case intake platform called ConvergeHEALTH Safety to transform pharmacovigilance (PV) and address the industry’s operational safety challenges. After initial implementation, Sanofi has already reportedly improved its case quality and enhanced case processing efficiencies within PV by automating the case intake process, which allow Sanofi to focus its attentions on the remaining adverse event case process.
This collaboration has been over two years in the making, as the parties have been working towards designing, developing and implementing a solution and approach that combines Deloitte’s platform with both Sanofi’s and Deloitte’s know-how.
According to Deloitte and Sanofi, the intake platform can provide:
- Improved case quality versus traditional manual data entry.
- Significantly reduced end-to-end case processing times via simplified processing and quality improvements during case intake and data entry.
- Continuous improvements of data science model efficiencies with the assistance of active monitoring.
“This collaborative initiative is a shining example of using advanced technologies in a highly-regulated area that not only leads with innovation and accelerates quality/efficiencies, but allows pharmacovigilance to focus on what’s most important—the safety of our patients,” says Anand Ramanathan, Sanofi’s head of digital pharmacovigilance.